NCT07404566Completed
Utility of MicroRNAs for Diagnosing Hepatocellular Carcinoma in Hepatitis C Patients
The Merits of Implementing microRNAs for Diagnosing Hepatocellular Carcinoma Among Hepatitis C Patients
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
This study evaluates a target population of patients with Hepatitis C virus (HCV) infection, including those with complications like liver cirrhosis (LC) and hepatocellular carcinoma (HCC), to investigate the diagnostic utility of a specific panel of microRNAs (miRNAs). The intervention involves quantifying the plasma expression (PE) levels of MiR-21, 1246, 205, 29a-3p, and 497 via PCR and comparing them to healthy controls to determine their efficacy as biomarkers. The primary outcome is to assess the sensitivity, specificity, and overall accuracy of these miRNAs in differentiating HCC from cirrhotic and non-cirrhotic HCV cases, aiming to establish more reliable screening tools than current standard biomarkers like alpha-fetoprotein (AFP).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 84 (actual)
- First submitted
- 5 Feb 2026
- Start date
- 15 Aug 2025
- Primary completion date
- 25 Nov 2025
- Lead sponsor
- Benha University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07404566
What you commit to
- Study type: Observational
- Participants enrolled: 84
- From 15 Aug 2025 to the primary completion date, 25 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Advanced stage of hepatic cirrhosis with portal hypertension or hepatorenal failure.
- Hepatic malignancies other than HCC.
- Alcoholic fatty liver disease
Other
- Bilharzial pre-portal fibrosis.
- hepatosteatosis.
Who the study is looking for
- Newly diagnosed HCV infection.
- Chronic uncomplicated HCV infection.
- HCV complicated with liver cirrhosis.
- HCV complicated with HCC on top of cirrhosis.
- Willingness to participate and sign written informed consent.
Age in the registry: 19 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alexandria Faculty of medicine Coordinator of this site? Confirm its status | Alexandria | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.